Brad Stair, MD
Interventional Cardiology · New Haven, CTNPI 1275775488
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,988 of the $7,289 with a category attached, or 82.1%. 17 manufacturers reported payments, led by Abbott at 30.3% of the total. Reporting peaked in 2019 at $2,811 and has fallen 72.0% since, to $787 in 2025.
Across 121 payments — averaging $60.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$1K
- Edwards Lifesciences$1K
- Medtronic$746
- Abiomed$348
- W. L. Gore & Associates, Inc.$304
- plus $883 from 11 others
What the payments were for
- Travel & lodging$1,30118%
- Food & beverage$5,98882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $2,206 |
| Boston Scientific | 40 | $1,488 |
| Edwards Lifesciences | 23 | $1,313 |
| Medtronic(2 entities) | 12 | $746 |
| Abiomed | 8 | $348 |
| W. L. Gore & Associates, Inc. | 3 | $304 |
| Silk Road Medical, Inc. | 1 | $298 |
| Shockwave Medical, Inc | 2 | $170 |
| Livanova USA, Inc. | 2 | $162 |
| Novo Nordisk | 2 | $45 |
| Cardiovascular Systems Inc. | 3 | $42 |
| GSK | 2 | $41 |
| Angiodynamics, Inc. | 2 | $40 |
| Cardiva Medical, Inc. | 1 | $29 |
| Biosense Webster, Inc. | 1 | $28 |
| Medicomp Inc | 1 | $16 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$1,872
- ENROUTE Transcarotid Neuroprotection System$595
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$395
- ENROUTE Transcarotid Stent$298
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$298
- Edwards SAPIEN 3 Transcatheter Heart Valve$296
- CoreValve Evolut$245
- GENERAL - STRUCTURAL HEART$225
- Impella$158
- LifeSPARC$142
- WATCHMAN Access System$141
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$138
- COREVALVE EVOLUT R$136
- GORE CARDIOFORM Septal Occluder$135
- GENERAL ATHERECTOMY$134
- COMET$124
- SAPIEN 3 Ultra RESILIA$113
- Watchman$112
How this compares
$7,289 in reported general payments places this provider in the 55th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 22 | $506,834 |
| EliquisApixaban | 254 | $276,176 |
| EntrestoSacubitril/Valsartan | 82 | $119,393 |
| JardianceEmpagliflozin | 91 | $91,851 |
| BrilintaTicagrelor | 78 | $76,883 |
| Repatha SureclickEvolocumab | 78 | $70,673 |
| XareltoRivaroxaban | 55 | $52,848 |
| Praluent PenAlirocumab | 40 | $34,759 |
| VascepaIcosapent Ethyl | 14 | $7,533 |
| Metoprolol Succinate | 648 | $7,135 |
| Atorvastatin Calcium | 527 | $5,079 |
| Losartan Potassium | 247 | $2,672 |
| Carvedilol | 201 | $1,955 |
| ClopidogrelClopidogrel Bisulfate | 194 | $1,839 |
| Torsemide | 120 | $1,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $12 | $52,84855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in New Haven
- Amit VoraNew Haven$409K
- Michael NannaNew Haven$60K
- Sameer NagpalNew Haven$43K
- Michael ChrissoherisNew Haven$24K
- Hari DeshpandeNew Haven$23K
- Samit ShahNew Haven$19K
- Yasin HussainNew Haven$13K
- Chirag ShahNew Haven$5K
- Scott WillisNew Haven$4K
- Rabih TabetNew Haven$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.